Fusion oncoproteins arise when a gene fuses with another gene and acquires new abilities. Such abilities can include the formation of biomolecular condensates, “droplets” of concentrated proteins, DNA or RNA.
MIDDLETON, Wis., Dec. 3, 2025 /PRNewswire/ — Natus Medical Incorporated announced the electrographic status epilepticus diagnosis capability of its BrainWatch point-of-care EEG solution, featuring integrated Persyst analysis software which has received 510(k) clearance from the U.S. Food and Drug Administration.
BEIJING, Dec. 3, 2025 /PRNewswire/ — Wingderm® announces that its Renuva 1550nm non-ablative fractional laser system has obtained MDR certification in the European Union, marking a significant regulatory milestone for the device within the EU market.
Carlsmed (Nasdaq:CARL) announced today that it began the U.S. launch of its Aprevo technology platform for cervical fusion surgeries.
Medtronic (NYSE: MDT)+
announced today that the FDA cleared its Hugo robotic-assisted surgery system for use in urologic surgical procedures.
Preliminary studies find derivatives of the compound, known as verticillin A, can kill some types of glioma cells.
Inspired by traditional acupuncture, the approach has potential to impact all implantable bioelectronic devices, enabling applications such as hypertension mitigation.
The test, which runs on the cobas liat system, is said to deliver results in 15 minutes.
The Vanquish device’s clinical data demonstrated an elimination of MRI visible intermediate risk disease in 91% of patients after a single procedure.
ST. PAUL, Minn., Dec. 3, 2025 /PRNewswire/ — Astrin Biosciences, a cancer intelligence company transforming how cancer is detected and treated through deep proteomics and AI, announced the launch of Certitude™, the first-of-its-kind, non-imaging, blood-based early cancer detection test. Results from the latest study will be presented at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 10–14, 2025.